Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator, BAY 41-8543, are modulated by nitric oxide

scientific article

Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator, BAY 41-8543, are modulated by nitric oxide is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1152/AJPHEART.01101.2009
P932PMC publication ID2957355
P698PubMed publication ID20639220

P50authorBobby NossamanQ83824922
Subramanyam N MurthyQ89782835
Philip J. KadowitzQ125134318
Adeleke M BadejoQ125134349
Edward A PankeyQ43160703
P2093author name stringVaughn E Nossaman
Chandrika B Kannadka
Manish Bhartiya
P2860cites workActivation of purified guanylate cyclase by nitric oxide requires heme. Comparison of heme-deficient, heme-reconstituted and heme-containing forms of soluble enzyme from bovine lungQ72538837
Purification and properties of heme-deficient hepatic soluble guanylate cyclase: Effects of heme and other factors on enzyme activation by NO, NO-heme, and protoporphyrin IXQ72540973
NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potentialQ24656131
NO-independent regulatory site on soluble guanylate cyclaseQ32165040
Molecular cloning and expression of cDNAs coding for soluble guanylate cyclase from rat lungQ33258194
NO-independent, haem-dependent soluble guanylate cyclase stimulatorsQ34906036
Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertensionQ34957241
Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studiesQ35044042
NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principleQ35044464
Nitric oxide-sensitive guanylyl cyclase: structure and regulationQ35863606
Clinical potential of nitric oxide-independent soluble guanylate cyclase activatorsQ36269513
Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilationQ36330594
The primary structure of the 70 kDa subunit of bovine soluble guanylate cyclaseQ36416369
Pulmonary vasodilator responses to sodium nitrite are mediated by an allopurinol-sensitive mechanism in the rat.Q37100160
Cyclic nucleotides and platelet aggregation effect of aggregating agents on the activity of cyclic nucleotide-metabolizing enzymesQ39111945
Stimulation of guanylate cyclase by sodium nitroprusside, nitroglycerin and nitric oxide in various tissue preparations and comparison to the effects of sodium azide and hydroxylamineQ39140610
Restoration of the responsiveness of purified guanylate cyclase to nitrosoguanidine, nitric oxide, and related activators by heme and hemeproteins. Evidence for involvement of the paramagnetic nitrosyl-heme complex in enzyme activationQ39218847
Relaxation of bovine coronary artery and activation of coronary arterial guanylate cyclase by nitric oxide, nitroprusside and a carcinogenic nitrosoamineQ39269807
Inhibition of human platelet aggregation by S-nitrosothiols. Heme-dependent activation of soluble guanylate cyclase and stimulation of cyclic GMP accumulationQ41534405
Expression of soluble guanylyl cyclase. Catalytic activity requires two enzyme subunitsQ41718282
YC-1, a novel activator of platelet guanylate cyclaseQ42275468
Increased responsiveness of the hepatic guanylate cyclase-guanosine 3′,5′-monophosphate system to nitrosoguanidine following partial hepatectomyQ42445794
Expression of soluble guanylate cyclase activity requires both enzyme subunitsQ42464263
NO-independent stimulators of soluble guanylate cyclaseQ43558550
Metabolites of orally active NO-independent pyrazolopyridine stimulators of soluble guanylate cyclaseQ43950505
Purification of soluble guanylate cyclase enzyme from human plateletsQ44251326
Mechanisms of nitric oxide independent activation of soluble guanylyl cyclaseQ44445674
Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambsQ45091740
Effects of BAY 41-2272, a soluble guanylate cyclase activator, on pulmonary vascular reactivity in the ovine fetus.Q45193709
Pulmonary vascular effects of nitric oxide-cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep.Q46554951
Effect of BAY 41-2272 in the pulmonary hypertension induced by heparin-protamine complex in anaesthetized dogs.Q48632087
Activation of purified soluble guanylate cyclase by endothelium-derived relaxing factor from intrapulmonary artery and vein: stimulation by acetylcholine, bradykinin and arachidonic acid.Q50909381
Dissimilarities between methylene blue and cyanide on relaxation and cyclic GMP formation in endothelium-intact intrapulmonary artery caused by nitrogen oxide-containing vasodilators and acetylcholine.Q50912436
BAY 41-2272, a Direct Activator of Soluble Guanylate Cyclase, Reduces Right Ventricular Hypertrophy and Prevents Pulmonary Vascular Remodeling during Chronic Hypoxia in Neonatal RatsQ58351224
Endothelium-derived relaxant factor inhibits platelet activationQ69819466
Activation of soluble guanylate cyclase by NO-hemoproteins involves NO-heme exchange. Comparison of heme-containing and heme-deficient enzyme formsQ69878955
Soluble guanylate cyclase from rat lung exists as a heterodimerQ69881953
Evidence for the inhibitory role of guanosine 3', 5'-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilatorsQ72462196
P433issue4
P304page(s)H1153-9
P577publication date2010-07-16
P1433published inAmerican Journal of Physiology Heart and Circulatory PhysiologyQ3193662
P1476titlePulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator, BAY 41-8543, are modulated by nitric oxide
P478volume299

Reverse relations

cites work (P2860)
Q42502151Analysis of responses to glyceryl trinitrate and sodium nitrite in the intact chest rat.
Q42244904Chronic intratracheal application of the soluble guanylyl cyclase stimulator BAY 41-8543 ameliorates experimental pulmonary hypertension
Q41894813Direct sGC activation bypasses NO scavenging reactions of intravascular free oxy-hemoglobin and limits vasoconstriction
Q37734554Inhalative and intravenous stimulation of soluble guanylate cyclase reduces pulmonary vascular resistance and increases cardiac output in experimental septic shock
Q36532454Pathophysiology of hypertension in the absence of nitric oxide/cyclic GMP signaling
Q47977733Peroxynitrite has potent pulmonary vasodilator activity in the rat.
Q34720361Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme
Q53462040Relaxant effect of a metal-based drug in human corpora cavernosa and its mechanism of action.
Q38818645Soluble Guanylate Cyclase Stimulators and Activators: Novel Therapies for Pulmonary Vascular Disease or a Different Method of Increasing cGMP?
Q35010064Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease
Q35075847Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Q38000562Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications.
Q38093420Stimulators of soluble guanylyl cyclase: future clinical indications
Q34179857Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension.
Q36923923The sGC activator BAY 60-2770 has potent erectile activity in the rat.
Q54185546Vascular dysfunctions in the isolated aorta of double-transgenic hypertensive mice developing aortic aneurysm.

Search more.